Pier Luigi Zinzani

Pier Luigi Zinzani has led pivotal Italian and European trials in rare T-cell and NK/T-cell lymphomas, contributing to the evidence base for novel agents in these challenging subtypes. His work encompasses EATL, ENKTL, and other rare T-lymphoid malignancies, with a focus on immunotherapy, PI3K inhibitors, and antibody-drug conjugates. He is among the highest-publishing European hematologists and a central figure in Italian lymphoma research.